• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis.

作者信息

Mansourian Marjan, Ghasemi Ms Khojasteh, Khorsandi PhD Danial, Vaseghi Golnaz

机构信息

Department of Epidemiology and Biostatistics, Health School, Isfahan University of Medical Sciences, Isfahan, Iran.

Student Research Committee, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.

出版信息

Am J Ther. 2020 Sep/Oct;27(5):e541-e543. doi: 10.1097/MJT.0000000000001008.

DOI:10.1097/MJT.0000000000001008
PMID:31107252
Abstract
摘要

相似文献

1
Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis.转移性激素敏感性前列腺癌所有可用治疗方法的比较有效性：一项网状Meta分析。
Am J Ther. 2020 Sep/Oct;27(5):e541-e543. doi: 10.1097/MJT.0000000000001008.
2
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.在转移性激素敏感性前列腺癌男性患者中，在雄激素剥夺治疗基础上加用阿比特龙：一项系统评价和荟萃分析。
Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8.
3
Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?转移性激素敏感型前列腺癌患者是否仍需要接受雄激素剥夺单药治疗？
Eur Urol Focus. 2019 Mar;5(2):114-116. doi: 10.1016/j.euf.2018.11.008. Epub 2018 Nov 24.
4
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.加速和改善转移性激素敏感型前列腺癌治疗评估的证据综合。
Eur Urol Focus. 2019 Mar;5(2):137-143. doi: 10.1016/j.euf.2019.01.005. Epub 2019 Feb 1.
5
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.阿比特龙、多西他赛或安慰剂联合雄激素剥夺疗法用于激素敏感性晚期前列腺癌的成本效益分析。
Einstein (Sao Paulo). 2019 Mar 7;17(2):eGS4414. doi: 10.31744/einstein_journal/2019GS4414.
6
[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].新型内分泌治疗延长去势抵抗性前列腺癌患者生存期
Ugeskr Laeger. 2013 Sep 30;175(40):2328-32.
7
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!阿比特龙还是多西他赛用于去势敏感性转移性前列腺癌？这是个问题！
Eur Urol. 2018 Jan;73(1):147-148. doi: 10.1016/j.eururo.2017.07.030. Epub 2017 Aug 8.
8
Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?转移性前列腺癌的原发灶治疗：标准治疗方法是什么？
Cancer J. 2020 Jan/Feb;26(1):83-86. doi: 10.1097/PPO.0000000000000430.
9
Prostate cancer: The androgen receptor remains front and centre.前列腺癌：雄激素受体仍然是核心要点。
Nat Rev Clin Oncol. 2013 Mar;10(3):126-8. doi: 10.1038/nrclinonc.2013.14. Epub 2013 Feb 5.
10
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.英国国家卫生与临床优化研究所（NICE）关于卡巴他赛用于先前接受过含多西他赛方案治疗的激素难治性转移性前列腺癌的指南。
Lancet Oncol. 2012 Jun;13(6):573-4. doi: 10.1016/s1470-2045(12)70220-6.

引用本文的文献

1
Chemotherapy and Heart-Specific Mortality in Elderly Men with Prostate Cancer: A Propensity Score Matching Analysis.老年前列腺癌男性患者的化疗与心脏特异性死亡率：一项倾向评分匹配分析
PLoS One. 2025 Apr 11;20(4):e0318429. doi: 10.1371/journal.pone.0318429. eCollection 2025.
2
Biomedical applications of engineered heparin-based materials.工程化肝素基材料的生物医学应用。
Bioact Mater. 2023 Aug 10;31:87-118. doi: 10.1016/j.bioactmat.2023.08.002. eCollection 2024 Jan.
3
Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change.
在晚期前列腺癌中重复进行网络荟萃分析：案例研究与变革建议。
Syst Rev. 2022 Dec 16;11(1):274. doi: 10.1186/s13643-022-02137-6.